🇺🇸 FDA
Patent

US 9732070

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/41A61K31/506

Quick answer

US patent 9732070 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/41, A61K31/506, A61P, A61P1/00